Novimmune SA, a Geneva, Switzerland-based drug discovery and development company, closed a CHF60m (approximately $66m) Series B financing.
The round was led by London-based Rosetta Capital Limited with participation from new private investors as well as existing investors. In conjunction with the investment, Dr. Jonathan Hepple, Partner at Rosetta, joined Novimmune’s Board of Directors.
Led by Jack Barbut, CEO, Novimmune is advancing NI-0501, a clinical-stage drug candidate for a life threatening disease, and NI-0101, a clinical-stage anti-TLR4 antibody, and the kappa/lambda body™ bispecific drug platform to selectively inhibit CD47 on cancer cells.
FinSMEs
18/02/2014